LC
VERV

Lindbrook Capital’s Verve Therapeutics VERV Stock Holding History

Lindbrook Capital’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$4.25K Hold
929
– – ﹤0.01% 2020
2024
Q4 		$5.24K Buy
929
+108
+13% +$609 ﹤0.01% 1963
2024
Q3 		$3.97K Sell
821
-342
-29% -$1.99K ﹤0.01% 2108
2024
Q2 		$5.67K Buy
1,163
+852
+274% +$5.36K ﹤0.01% 1940
2024
Q1 		$4.13K Sell
311
-111
-26% -$1.47K ﹤0.01% 1981
2023
Q4 		$5.88K Buy
422
+332
+369% +$4.12K ﹤0.01% 1799
2023
Q3 		$1.19K Buy
+90
New +$1.45K ﹤0.01% 2303
2022
Q4 		– Sell
-38
Closed -$1K – 3021
2022
Q3 		$1K Buy
+38
New +$1.21K ﹤0.01% 2516
2021
Q3 		– Sell
-300
Closed -$18K – 2007
2021
Q2 		$18K Buy
+300
New +$12.5K ﹤0.01% 829

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Lindbrook Capital's VERV Position: Q1 2025 in Review

Lindbrook Capital held its Verve Therapeutics (VERV) position steady in Q1 2025 at 929 shares worth $4.25K. The position accounts for ﹤0.01% of the portfolio, ranked #2020.

Lindbrook Capital first reported a position in VERV in Q2 2021 and has held it in 9 quarters since. The position peaked at $18K in Q2 2021. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • Lindbrook Capital held 929 shares of Verve Therapeutics worth $4.25K as of Q1 2025.
  • Lindbrook Capital left its Verve Therapeutics share count unchanged in Q1 2025.
  • Verve Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2020 holding.
  • Lindbrook Capital first reported a position in Verve Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • Lindbrook Capital's Verve Therapeutics position peaked at $18K in Q2 2021.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.